J
James D. Neaton
Researcher at University of Minnesota
Publications - 352
Citations - 68183
James D. Neaton is an academic researcher from University of Minnesota. The author has contributed to research in topics: Risk factor & Blood pressure. The author has an hindex of 101, co-authored 331 publications receiving 64719 citations. Previous affiliations of James D. Neaton include University of Pittsburgh & Medical Research Council.
Papers
More filters
Journal ArticleDOI
The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms.
TL;DR: A randomized trial of early ART will provide the best data for assessment of the net risks and benefits of ART use on CVD, and CVD risk may increase with some ART, and this risk may be class-specific and/or drug-specific.
Journal ArticleDOI
Evolution of Vaginal Candida Species Recovered from Human Immunodeficiency Virus-Infected Women Receiving Fluconazole Prophylaxis: The Emergence of Candida glabrata?
Jose A. Vazquez,Jack D. Sobel,Grace Peng,Lynn Steele-Moore,Paula Schuman,William J. Holloway,James D. Neaton +6 more
TL;DR: Fluconazole had an early and persistent effect on the vaginal mycoflora, with the emergence of C. glabrata vaginal colonization within the first 6 months, which can be attributed to the reduction in vaginal C. albicans colonization; however, C.glabrATA colonization rapidly supervened.
Journal ArticleDOI
Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV-positive patients taking antiretroviral therapy.
Claude Béténé A C.B.A. Dooko,Stéphane De Wit,Jacqueline J. Neuhaus,Adrian Palfreeman,Rosalie R. Pepe,James J.S. Pankow,James D. Neaton +6 more
TL;DR: These findings indicate that low-grade systemic inflammation is an underlying factor in the pathogenesis of diabetes.
Journal ArticleDOI
When to start antiretroviral therapy: the need for an evidence base during early HIV infection
TL;DR: There is currently no evidence from randomized controlled trials to suggest that a strategy of initiating ART when the CD4 count is above 350 cells/μl results in benefit to the HIV+ person and data from observational studies are inconsistent.
Journal ArticleDOI
Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy
John D. Baxter,Thomas C. Merigan,Deborah Wentworth,James D. Neaton,Marie L. Hoover,Richard M. W. Hoetelmans,Stephen C. Piscitelli,Werner Verbiest,Douglas L. Mayers,Douglas L. Mayers +9 more
TL;DR: In salvage therapy, both the number of active drugs and the DL for each drug in the new regimen determine the antiviral response.